Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 09, 2023
PCT Stock Jumps 16.19% and Emerges as Top Gainer This Month

PCT Stock Jumps 16.19% and Emerges as Top Gainer This Month

PureCycle Technologies (PCT) emerged as one of the leading gainers in the Industrial Machinery Industry for the month, with a notable rise of +16.19% to reach $7.25 per share. This was revealed in a recent analysis by A.I.dvisor, which examined 342 stocks in the sector for the month ending May 5, 2023. The study found that 263 stocks (76.92%) exhibited an Uptrend while 79 stocks (23.08%) were on a Downtrend.

In an encouraging development for PCT, the 10-day moving average for the stock crossed above the 50-day moving average on May 04, 2023. This bullish crossover is a potential buy signal and suggests that the trend has turned upwards. A.I.dvisor's analysis reveals that in eight out of nine past instances when the 10-day crossed above the 50-day, PCT continued to move higher over the following month. Based on this historical trend, the odds of a continued upward trend for PCT are currently estimated to be 89%.

Additionally, A.I.dvisor's data indicates that over the last year, PCT has shown a moderate correlation with BLDP. These two tickers moved together in tandem about 45% of the time, suggesting that there could be some statistical probability that if PCT sees price increases, BLDP could also experience a similar rise. This latest analysis by A.I.dvisor offers valuable insights for investors looking to make informed decisions about their investment strategies.

Related Ticker: PCT

Momentum Indicator for PCT turns positive, indicating new upward trend

PCT saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PCT's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PCT just turned positive on July 27, 2026. Looking at past instances where PCT's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PCT advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for PCT moved below the 200-day moving average on July 31, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PCT broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PCT entered a downward trend on August 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PCT's P/B Ratio (93.458) is very high in comparison to the industry average of (12.631). PCT has a moderately low P/E Ratio (0.000) as compared to the industry average of (84.340). PCT's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (2.020). PCT's Dividend Yield (0.000) is considerably lower than the industry average of (0.007). P/S Ratio (96.154) is also within normal values, averaging (229.120).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Industry description

Companies in the industrial specialties industry process basic materials and minerals into various specialty products, such as flat and safety glass, fire retardant products, paints and coatings. Examples of companies operating in this industry are Sherwin-Williams Company, PPG Industries, Inc. and RPM International Inc.

Market Cap

The average market capitalization across the Industrial Specialties Industry is 2.44B. The market cap for tickers in the group ranges from 344.07K to 23.67B. VLTO holds the highest valuation in this group at 23.67B. The lowest valued company is ATMFF at 344.07K.

High and low price notable news

The average weekly price growth across all stocks in the Industrial Specialties Industry was -2%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -15%. LIQT experienced the highest price growth at 12%, while RAIN experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Industrial Specialties Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 46% and the average quarterly volume growth was 5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 78
P/E Growth Rating: 76
Price Growth Rating: 65
SMR Rating: 87
Profit Risk Rating: 91
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
PCT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry IndustrialSpecialties

Profile
Details
Industry
N/A
Address
20 North Orange Avenue
Phone
+1 877 648-3565
Employees
174
Web
https://www.purecycle.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Strykerβ€”diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY),Β AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of Β₯1.81 trillion, up 3.7% YoY, on track for its full-year target of Β₯2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.